Cargando…
The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance
The rise of the synthetic opioid epidemic has time and time again brought criticism on China and India, the world’s two main producers of fentanyl and its chemical precursors. In the past few years, the two countries have attempted to strengthen regulations over fentanyl production and distribution,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871795/ https://www.ncbi.nlm.nih.gov/pubmed/35206258 http://dx.doi.org/10.3390/ijerph19042074 |
_version_ | 1784657081077334016 |
---|---|
author | Wang, Chao Lassi, Nicholas Zhang, Xiaohan Sharma, Vinay |
author_facet | Wang, Chao Lassi, Nicholas Zhang, Xiaohan Sharma, Vinay |
author_sort | Wang, Chao |
collection | PubMed |
description | The rise of the synthetic opioid epidemic has time and time again brought criticism on China and India, the world’s two main producers of fentanyl and its chemical precursors. In the past few years, the two countries have attempted to strengthen regulations over fentanyl production and distribution, though its effects on global drug governance remain under scrutiny. This study used qualitative and comparative methods to investigate the current regulatory landscape for fentanyl, including its efficiency and potential loopholes in China and India. It concludes that although both China and India are actively and significantly attempting to step away from the global fentanyl supply chain, these efforts remain ineffective due to institutional loopholes, namely inadequate legislation and fragmented regulatory structures. From insights gained on global drug governance, we recommend a binding international convention concentrated on controlling fentanyl and its related substances, with further bilateral and multilateral cooperation among states as necessary complementation. |
format | Online Article Text |
id | pubmed-8871795 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88717952022-02-25 The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance Wang, Chao Lassi, Nicholas Zhang, Xiaohan Sharma, Vinay Int J Environ Res Public Health Article The rise of the synthetic opioid epidemic has time and time again brought criticism on China and India, the world’s two main producers of fentanyl and its chemical precursors. In the past few years, the two countries have attempted to strengthen regulations over fentanyl production and distribution, though its effects on global drug governance remain under scrutiny. This study used qualitative and comparative methods to investigate the current regulatory landscape for fentanyl, including its efficiency and potential loopholes in China and India. It concludes that although both China and India are actively and significantly attempting to step away from the global fentanyl supply chain, these efforts remain ineffective due to institutional loopholes, namely inadequate legislation and fragmented regulatory structures. From insights gained on global drug governance, we recommend a binding international convention concentrated on controlling fentanyl and its related substances, with further bilateral and multilateral cooperation among states as necessary complementation. MDPI 2022-02-12 /pmc/articles/PMC8871795/ /pubmed/35206258 http://dx.doi.org/10.3390/ijerph19042074 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wang, Chao Lassi, Nicholas Zhang, Xiaohan Sharma, Vinay The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title | The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title_full | The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title_fullStr | The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title_full_unstemmed | The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title_short | The Evolving Regulatory Landscape for Fentanyl: China, India, and Global Drug Governance |
title_sort | evolving regulatory landscape for fentanyl: china, india, and global drug governance |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871795/ https://www.ncbi.nlm.nih.gov/pubmed/35206258 http://dx.doi.org/10.3390/ijerph19042074 |
work_keys_str_mv | AT wangchao theevolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT lassinicholas theevolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT zhangxiaohan theevolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT sharmavinay theevolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT wangchao evolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT lassinicholas evolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT zhangxiaohan evolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance AT sharmavinay evolvingregulatorylandscapeforfentanylchinaindiaandglobaldruggovernance |